文献速递白血病造血干细胞移植与细胞治疗

达沙替尼联合泼尼松诱导及巩固治疗成人费城染色体阳性急性淋巴细胞白血病:单臂、多中心、2期试验

Dasatinib plus prednisone as induction and consolidation for adults with Ph-positive acute lymphoblastic leukaemia: A single-arm, multicentre, phase 2 trial.
PubMed 文献 · Br J Haematol · 2023-07-11

该2期单臂多中心试验纳入41例初诊费城染色体阳性急性淋巴细胞白血病成人患者,采用达沙替尼联合泼尼松无化疗方案诱导和早期巩固。完全缓解率95%(39/41),诱导期死亡2例老年患者。中位随访15.4个月,首次完全缓解期接受造血干细胞移植者2年无病生存率100%,单纯化疗者33%。

要点

  • 达沙替尼联合泼尼松无化疗诱导和早期巩固方案在初诊费城染色体阳性急性淋巴细胞白血病中有效且耐受良好。
  • 完全缓解率95%(39/41),诱导期死亡2例老年患者。
  • 首次完全缓解期接受异基因造血干细胞移植者2年无病生存率100%,单纯化疗者33%。

核心结论

  • 达沙替尼联合泼尼松无化疗诱导和早期巩固方案在初诊费城染色体阳性急性淋巴细胞白血病中有效且耐受良好。
  • 异基因造血干细胞移植在无化疗诱导后 confer 明确的生存优势。

研究设计与样本

  • 单臂、多中心、2期试验,纳入41例初诊费城染色体阳性急性淋巴细胞白血病成人患者,来自15家医院。
  • 方案为达沙替尼联合泼尼松,作为诱导(第I疗程)和早期巩固(第II和第III疗程)。
  • 试验注册于www.chictr.org.cn,注册号ChiCTR2000038053。

主要发现

  • 完全缓解率95%(39/41),包括2例老年患者诱导期死亡。
  • 第III疗程结束时,25.6%(10/39)患者达到完全分子学缓解。
  • 中位随访15.4个月,首次完全缓解期接受造血干细胞移植者2年无病生存率100%,单纯化疗者33%。
  • 截尾于造血干细胞移植时,年轻和老年患者2年无病生存率分别为51%和45%(p = 0.987)。
  • 2年总生存率:未移植者45%,复发后移植者86%,首次完全缓解期移植者100%。

关键数值与推荐

  • 完全缓解率95%(39/41)。
  • 第III疗程结束时完全分子学缓解率25.6%(10/39)。
  • 中位随访15.4个月,首次完全缓解期移植者2年无病生存率100% vs 单纯化疗者33%。
  • 截尾于移植时,年轻患者2年无病生存率51% vs 老年患者45%(p = 0.987)。
  • 2年总生存率:未移植者45% vs 复发后移植者86% vs 首次完全缓解期移植者100%。

临床怎么用

  • 该无化疗诱导和早期巩固方案可用于初诊费城染色体阳性急性淋巴细胞白血病成人患者。
  • 异基因造血干细胞移植在无化疗诱导后 confer 明确的生存优势。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To reducing chemotherapy-related toxicity, the chemo-free regimens become a new trend of Ph + ALL treatment. Therefore, we conducted a phase 2 trial of dasatinib plus prednisone, as induction (Course I) and early consolidation (Courses II and III) treating newly diagnosed Ph + ALL. The trial was registered at www.chictr.org.cn, ChiCTR2000038053. Forty-one patients were enrolled from 15 hospitals. The complete remission (CR) was 95% (39/41), including two elderly induction deaths. By the end of Course III, 25.6% (10/39) of patients achieved a complete molecular response. With a median follow-up of 15.4 months, 2-year disease-free survival (DFS) were 100% and 33% for patients who receiving haematopoietic stem cell transplantation (HSCT) at CR1 and receiving chemotherapy alone respectively. When censored at time of HSCT, 2-year DFS were 51% and 45% for young and elderly patients (p = 0.987). 2-year overall survival were 45%, 86% and 100% for patients without HSCT, receiving HSCT after relapse and receiving HSCT at CR1 respectively. A total of 12 patients had marrow recurrences and one had CNS relapse, with 38% occurred early (between Courses I and III). IKZF1 gene deletion was shown to be associated with relapse (p = 0.019). This chemo-free induction and early consolidation regimen was efficacious and well-tolerated in de novo Ph + ALL. Allogeneic HSCT conferred definite survival advantage after chemo-free induction.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Xie M, Lu Y, Ouyang G, et al. Dasatinib plus prednisone as induction and consolidation for adults with Ph-positive acute lymphoblastic leukaemia: A single-arm, multicentre, phase 2 trial. Br J Haematol. 2023. PMID: 37434414. doi:10.1111/bjh.18975

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。